Last modified: 22 May 2019 17:07
The will comprise lectures, tutorials and seminars. The curriculum will provide an in-depth look at pharmacovigilance, communication with regulators and the public using examples from both first and third world countries and will include detection of adverse drug reactions; causality assessment; prevention of adverse drug reactions including correct prescribing, prevention of drug errors and promotion of rational drug use; and communication of risk-benefit information to the general public. It will also include an introduction to the commercialisation of scientific ideas in the form of Bio-Business covering the pharma industry, spin out companies, IPR and finance.
| Study Type | Postgraduate | Level | 5 |
|---|---|---|---|
| Term | Second Term | Credit Points | 15 credits (7.5 ECTS credits) |
| Campus | None. | Sustained Study | No |
| Co-ordinators |
|
||
Information on contact teaching time is available from the course guide.
2000 word essay on pharmacovigilance (50%); 500 word writing for the layman (20%); Presentation on a business model (30%).
There are no assessments for this course.
We have detected that you are have compatibility mode enabled or are using an old version of Internet Explorer. You either need to switch off compatibility mode for this site or upgrade your browser.
